Abstract
摘要
相似文献
1
Step care for asthma.哮喘的分级治疗
JAMA. 1988;260(4):543.
2
[What is assured in drug therapy of bronchial asthma?].[支气管哮喘药物治疗中可确保的是什么？]
Internist (Berl). 1993 Dec;34(12):1133-40.
3
4
The FDA-mandated trial of safety of long-acting beta-agonists in asthma: finality or futility?美国食品药品监督管理局要求进行的长效β受体激动剂治疗哮喘安全性试验：是定论还是徒劳？
Thorax. 2013 Feb;68(2):195-8. doi: 10.1136/thoraxjnl-2012-202414. Epub 2012 Aug 2.
5
Optimizing medications for poorly controlled asthma.优化治疗控制不佳的哮喘的药物
Am J Respir Crit Care Med. 2007 Sep 1;176(5):520-1; author reply 521-2. doi: 10.1164/ajrccm.176.5.520b.
6
Double or nothing? Treating exacerbations of asthma.孤注一掷？哮喘急性加重的治疗
Intern Med J. 2005 Dec;35(12):689-91. doi: 10.1111/j.1445-5994.2005.00995.x.
7
[Glucocorticoids in asthmatic crisis in children].
Arch Fr Pediatr. 1990 Apr;47(4):291-6.
8
[Modern asthma management. Getting a grip on the illness].[现代哮喘管理。掌控疾病]
MMW Fortschr Med. 2002 Mar 21;144(12):61.
9
What about add-on second-line controller therapy?附加二线控制疗法如何？
Chest. 2005 Mar;127(3):1077; author reply 1077-8. doi: 10.1378/chest.127.3.1077.
10
What drives prescription patterns in pediatric asthma management?是什么驱动了儿童哮喘管理中的处方模式？
J Allergy Clin Immunol. 2007 Oct;120(4):969-72. doi: 10.1016/j.jaci.2007.06.011. Epub 2007 Jul 16.
引用本文的文献
1
Chronic obstructive pulmonary disease in blacks and whites: mortality and morbidity.黑人和白人中的慢性阻塞性肺疾病：死亡率和发病率
J Natl Med Assoc. 1990 Jun;82(6):417-28.
2
Risk/benefit ratio of long-term treatment with beta 2-adrenoceptor agonists.β2肾上腺素能受体激动剂长期治疗的风险/效益比。
Lung. 1990;168 Suppl:168-76. doi: 10.1007/BF02718129.
Zotero 插件